We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Noninvasive Neurostimulator Helps Prevent Cluster Headaches

By HospiMedica International staff writers
Posted on 12 Dec 2018
Print article
Image: In clinical studies, vagus nerve stimulation applied at the neck reduced cluster headache incidence (Photo courtesy of electroCore).
Image: In clinical studies, vagus nerve stimulation applied at the neck reduced cluster headache incidence (Photo courtesy of electroCore).
A novel non-invasive vagus nerve stimulation (nVNS) device excites the nerve’s afferent fibers, leading to headache pain reduction.

The electroCore (Basking Ridge, NJ, USA) gammaCore is hand-held adjunctive therapy device indicated for the prevention of cluster headaches and for the treatment of the acute pain associated with episodic cluster headache and migraine. The portable device provides a mild electrical stimulation to the vagus nerve, without the potential side effects associated with commonly prescribed drugs. The self-administered treatment consists of three consecutive two-minute stimulations twice a day, with the first treatment applied within one hour of waking up and the second seven to 10 hours later; the device does not prevent migraines.

In two clinical studies, nVNS patients had 3.9 fewer cluster attacks per week than those who received standard of care (SOC). In addition, 40% of those patients who received gammaCore in addition to SOC experienced a 50% or greater reduction in weekly cluster attacks, compared to 8.3% of patients who received SOC alone. Also, a 57% decrease in the frequency of abortive medication use among those who received gammaCore plus SOC care was demonstrated, while those patients who received SOC alone did not experience a substantial reduction.

“Clearance of gammaCore for adjunctive use for the preventive treatment of cluster headache has the potential to help the approximately 350,000 Americans impacted by this debilitating condition, often referred to as a suicide headache,” said Frank Amato, CEO of electroCore. “We are pleased that cluster headache patients now have a FDA-cleared option, and one that is both safe and effective, especially given the difficulty in treating cluster headache and the limitations of current treatments.”

Cluster headache is a rare but extremely painful disorder characterized by recurring unilateral attacks. The condition is the least common type of headache disorder, occurring in 1-2 out of 1,000 individuals, affecting predominantly males, heavy smokers and those with a family history. Symptoms typically manifest by age 30. Frequently nicknamed “suicide headache” due to the severity of pain associated with their occurrence, cluster headache bouts occur rapidly and with variable frequency, but often at the same time each year or day and are often more frequent at night.

Related Links:
electroCore

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
24.5-inch Full HD 2D OLED Medical Monitor
PVM-2551MD

Print article

Channels

Surgical Techniques

view channel
Image: NeuroBlate NB3 FullFire 1.6mm laser probe is meant for use with the NeuroBlate System (Photo courtesy of Monteris Medical)

World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets

A new probe enhances the ablation capabilities for a broad spectrum of oncology and epilepsy targets, including pediatric applications, by incorporating advanced laser and cooling technologies to support... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more